Zymeworks and Merck collaborate on "bispecific" antibodies

08/29/2011 | Xconomy

Canada's Zymeworks agreed to partner with Merck & Co. to develop "bispecific" antibody drugs for cancer and autoimmune conditions. The deal entitles Zymeworks to as much as $187 million in upfront and milestone fees, plus tiered royalties. Merck will gain exclusive global rights to market resulting therapies.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA